WO2012074980A3 - Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives - Google Patents

Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives Download PDF

Info

Publication number
WO2012074980A3
WO2012074980A3 PCT/US2011/062350 US2011062350W WO2012074980A3 WO 2012074980 A3 WO2012074980 A3 WO 2012074980A3 US 2011062350 W US2011062350 W US 2011062350W WO 2012074980 A3 WO2012074980 A3 WO 2012074980A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
methods
treating
acetic acid
acid derivatives
Prior art date
Application number
PCT/US2011/062350
Other languages
French (fr)
Other versions
WO2012074980A2 (en
Inventor
Mary Katherine Delmedico
Original Assignee
Dara Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dara Biosciences, Inc. filed Critical Dara Biosciences, Inc.
Publication of WO2012074980A2 publication Critical patent/WO2012074980A2/en
Publication of WO2012074980A3 publication Critical patent/WO2012074980A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides indane acetic acids and their derivatives and methods for the treatment and/or prevention of autoimmune disorders and liver disorders using the same.
PCT/US2011/062350 2010-12-01 2011-11-29 Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives WO2012074980A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41870010P 2010-12-01 2010-12-01
US41871210P 2010-12-01 2010-12-01
US61/418,712 2010-12-01
US61/418,700 2010-12-01

Publications (2)

Publication Number Publication Date
WO2012074980A2 WO2012074980A2 (en) 2012-06-07
WO2012074980A3 true WO2012074980A3 (en) 2014-04-17

Family

ID=46172500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/062350 WO2012074980A2 (en) 2010-12-01 2011-11-29 Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives

Country Status (1)

Country Link
WO (1) WO2012074980A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP2844295A1 (en) 2012-05-03 2015-03-11 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
BR112015020139A2 (en) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc therapeutic compounds and their uses
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (en) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. Crystalline forms of therapeutic compounds and uses thereof
MX2017012319A (en) * 2015-03-26 2018-05-11 T3D Therapeutics Inc Methods of treating liver disease using indane acetic acid derivatives.
CN109688818A (en) 2016-09-08 2019-04-26 卡拉制药公司 Crystal form of therapeutic compounds and application thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011842A1 (en) * 2001-07-27 2003-02-13 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20030199564A1 (en) * 2000-02-28 2003-10-23 Garry Fenton Indane derivatives
US20060084680A1 (en) * 2002-12-20 2006-04-20 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20080249093A1 (en) * 2003-12-17 2008-10-09 Merck & Co., Inc. (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199564A1 (en) * 2000-02-28 2003-10-23 Garry Fenton Indane derivatives
WO2003011842A1 (en) * 2001-07-27 2003-02-13 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20060084680A1 (en) * 2002-12-20 2006-04-20 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20080249093A1 (en) * 2003-12-17 2008-10-09 Merck & Co., Inc. (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists

Also Published As

Publication number Publication date
WO2012074980A2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
WO2012074980A3 (en) Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
IL276153B (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency .
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
WO2014055996A3 (en) Rho kinase inhibitors
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
WO2012068109A3 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
WO2012021287A9 (en) Methods for the treatment and prevention of metabolic disorders
WO2011082245A3 (en) Metalloenzyme inhibitor compounds
ZA201306388B (en) Methods and compositions for treating,reducing,or preventing deterioration of the visual system of animals
MX2013011490A (en) Pyridopyrazine derivatives and their use.
WO2012051599A8 (en) Modulation neural pathways
WO2012082862A3 (en) Androgen receptor inhibitors and methods of use thereof
WO2012058529A3 (en) Metalloenzyme inhibitor compounds
WO2012094328A3 (en) Hedgehog antagonists having zinc binding moieties
WO2012082746A3 (en) Metalloenzyme inhibitor compounds
WO2012078519A3 (en) 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
IT1397446B1 (en) COMPOSITIONS COMPRISING AMINO ACIDS FOR PREVENTION AND / OR TREATMENT OF RENAL DISORDERS.
WO2012068332A9 (en) Methods for treating early stage or mild neurological disorders
WO2013033004A3 (en) Metalloenzyme inhibitor compounds
EP3328392A4 (en) Compounds, compositions and methods for prevention or treatment of liver and lipid-related conditions
EP3256455B8 (en) Method for the reduction of carboxylic acids or carbonic acid and their derivatives
GB201004761D0 (en) Method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11844808

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11844808

Country of ref document: EP

Kind code of ref document: A2